Sanofi is a leading multinational biopharmaceutical company that operates globally, with a strong commercial presence in the United States, Europe, and emerging markets. The company's business model centers on the research, development, and commercialization of innovative prescription drugs and vaccines. Following a strategic pivot to focus on high-growth, science-led biopharma assets, Sanofi operates primarily through three core segments: Specialty Care, Vaccines, and General Medicines. The Specialty Care division is the company's primary economic engine, driven largely by the blockbuster immunology drug Dupixent (developed in collaboration with Regeneron), alongside treatments for rare diseases, rare blood disorders, neurology, and oncology. The Vaccines segment is a global leader, offering a broad portfolio of pediatric, influenza, meningitis, and travel vaccines. The General Medicines segment includes established products for diabetes and cardiovascular conditions. In 2024-2025, Sanofi completed the separation of its Consumer Healthcare arm (Opella) to concentrate capital and management attention on its core biopharma pipeline. Geographically, the United States represents a major commercial profit pool, while Europe serves as a core R&D and manufacturing base. Sanofi's competitive position is bolstered by its strategic acquisitions, such as Genzyme, which strengthened its rare disease and biologics capabilities, and its ongoing investments in mRNA technology and AI-driven drug discovery.
